HomeCompanies › IONS

Ionis Pharmaceuticals

Most recent annual filing: 2026-02-26

Catalyst timeline

8 trackedQuarter catalyst calendar →
  1. Sefaxersen Ph3 topline2026Sefaxersen Ph3 topline, 2026, material
  2. Ulefnersen Ph3 topline2026Ulefnersen Ph3 topline, 2026, material
  3. Eplontersen ATTR-CM filing2026Eplontersen ATTR-CM filing, 2026, notable
  4. Pelacarsen filing2026Pelacarsen filing, 2026, notable
  5. Ionis corporate updateOct–Nov 2026Ionis corporate update, Oct–Nov 2026, material
  6. Bepirovirsen PDUFA dateOct 26, 2026Bepirovirsen PDUFA date, Oct 26, 2026, material
  7. Obudanersen Ph3 topline2027Obudanersen Ph3 topline, 2027, thesis-defining
  8. Olezarsen TRYNGOLZA filing2027Olezarsen TRYNGOLZA filing, 2027, material

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (29 active programs)

Technology platforms

MsPA backbone chemistry

Mesyl phosphoramidate backbone chemistry designed to improve therapeutic index and durability by increasing metabolic stability, improving potency and reducing non-specific protein interactions; multiple new programs in preclinical development

Bicycle technology · Bicycle Therapeutics

Bicyclic peptide technology licensing collaboration with Bicycle Therapeutics to expand LICA platform for delivery of oligonucleotides to skeletal and cardiac muscle and potentially across the blood-brain barrier via transferrin receptor 1 binding

Targets: transferrin receptor 1

Vect-Horus technology · Vect-Horus

Camelid-derived antibody platform licensed exclusively for systemic delivery of RNA-targeted therapeutics across the blood-brain barrier to CNS targets; first program advanced to preclinical development in 2025

Metagenomi gene editing · Metagenomi

Collaboration leveraging RNA-targeted therapeutics expertise combined with Metagenomi next-generation CRISPR-Cas gene editing systems to discover and develop drugs for validated and novel genetic targets; up to eight targets total

Vect-Horus · Vect-Horus

Systemic delivery platform for RNA-targeted therapeutics using camelid-derived single-domain antibodies to cross the blood-brain barrier and address CNS targets; focus area: central nervous system diseases

Discontinued (1)

Biotech Distilled coverage (1)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.